Spectrum Pharmaceuticals (SPPI) Stock Price, News & Analysis

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" SPPI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SPPI, but not buy additional shares or sell existing shares.
View SPPI analyst ratings or view top-rated stocks.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) announced its quarterly earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.21) earnings per share for the quarter, topping analysts' consensus estimates of ($0.28) by $0.07. During the same quarter in the previous year, the firm posted ($0.37) EPS.

2 employees have rated Spectrum Pharmaceuticals Chief Executive Officer Joseph Turgeon on Glassdoor.com. Joseph Turgeon has an approval rating of 47% among the company's employees. This puts Joseph Turgeon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Spectrum Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Verastem (VSTM), Exelixis (EXEL), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), OPKO Health (OPK), Bausch Health Companies (BHC), Sorrento Therapeutics (SRNE) and Zynerba Pharmaceuticals (ZYNE).